Download ValiSeek – VAL401-A NOVEL CANCER THERAPEUTIC

VAL401: A NOVEL CANCER THERAPEUTIC
COMPOSITION
KEY FEATURES
VAL401 comprises a novel cancer therapeutic that combines
Risperidone with Rumenic Acid as part of a non-toxic lipid
formulation in a gelatin capsules that is administered orally
being developed by ValiSeek Limited




Risperidone is safe and tolerable
Efficacy against various cancers
Simple and low cost manufacturing
Patent protected formulation
PROVEN RESULTS



VAL401 reduces cellular activity for multiple different cancer cells lines
Preclinical efficacy demonstrated in lung, prostate and pancreatic adenocarcinoma models, showing
reduced tumour growth rates and survival advantage
Dose of Risperidone is within the range licensed as safe and tolerable for CNS use
INTELLECTUAL PROPERTY
Issued US patents: US 9072743 and US 9375433 with further US and international patent applications pending
INITIAL TARGET – NON SMALL CELL LUNG CANCER Phase 2 clinical study underway completion due 2017
MARKET


Non Small Cell Lung Cancer accounts for 80% of
all lung cancer
The market was USD 5.1 billion in 2013,
projected to increase to USD7.9 billion in 2020
at a CAGR of 6.6%
Suzanne Dilly, ValiSeek Limited CEO
[email protected]
+44 7736270615